This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
Other/Multi
ASCO 2025 | May 30-June 3,2025
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors
Poster
Other/Multi
AMCP Nexus 2024 | October 14-17, 2024
A retrospective real-world evaluation of docetaxel-based treatments after standard of care (SOC) for patients with non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC)
Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Association of TROP2 quantitative continuous scoring
normalised membrane ratio with efficacy in Chinese patients
with advanced/metastatic non-small cell lung cancer treated
with datopotamab deruxtecan in TROPION-PanTumor02
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Poster
Dato-DXd
ESMO 2024 | September 13-17, 2024
Dato-DXd vs docetaxel in patients with advanced nonsquamous non-small cell lung cancer with brain metastases: Results from TROPION-Lung01
Oral
Dato-DXd
WCLC 2024 | September 7-10, 2024
Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01
Poster
Dato-DXd
ELCC 2025 | March 26-29, 2025
Effects of datopotamab deruxtecan (Dato-DXd) vs docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or
metastatic nonsquamous (NSQ) non-small cell lung cancer (NSCLC): Results from TROPION-LUNG01
Oral
Dato-DXd
ESMO Asia 2024 | December 6-8, 2024
Efficacy and safety of datopotamab deruxtecan in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): pooled analysis of TROPION-Lung01 and TROPION-Lung05
Poster
Dato-DXd
ACoP15 | November 10-13, 2024
Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Poster
T-DXd
ACCP 2024 | September 8-10, 2024
Exposure-response analyses of efficacy and safety of trastuzumab deruxtecan to inform dosing recommendations in HER2-mutant non–small cell lung cancer